EVOK
Evoke PharmaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
EVOK Profile
Evoke Pharma, Inc.
A specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases
420 Stevens Avenue, Suite 230, Solana Beach, California 92075
--
Evoke Pharma, Inc., was incorporated in Delaware on January 29, 2007. The company is a specialty pharmaceutical company focused on the development of drugs for the treatment of gastrointestinal diseases, gastrointestinal diseases and diseases. The company is developing Gimoti, an experimental metoclopramide nasal spray, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Diabetic gastroparesis is a gastrointestinal disease that affects millions of people worldwide and is characterized by slow or delayed gastric emptying and evidence of gastric retention without mechanical obstruction, and can cause a variety of serious digestive symptoms and other complications. Metoclopramide tablets and injections are currently the only products approved in the United States for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a new nasal spray of metoclopramide designed to provide systemic delivery of molecules through the nasal mucosa.
